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Abstract
A 36-year-old woman was found to have a low morning ACTH concentration despite a history of Addison’s disease. 
Past medical history: At the age of 23 years the subject developed Graves’s disease, which was treated with radioiodine. At about the 
same time, she claimed to have two episodes of pancreatitis treated with cholecystectomy. About seven months later she was euthyroid 
on L-thyroxine (TSH 1.51 mIU/mL) but was admitted with hypotension, hyponatraemia (sodium 109 mmol/L), and low morning cortisol 
(119 nmol/L). Further investigations confirmed primary adrenal failure with ACTH concentration of 779 pg/mL (ref. range 0–60) prior to 
the dose of hydrocortisone. About nine years later she complained about tiredness. Clinically she was normotensive and not pigmented. 
BMI 22.3 kg/m2. Periods were regular. ACTH concentration was surprisingly low (ACTH 8.53 pg/mL, ref. range 0–46), despite very low 
cortisol (3.37 nmol/L). She was admitted for further assessment. 
Investigations: Pituitary MRI scan was unremarkable. An insulin tolerance test was performed and showed a clear increase of ACTH 
(from 15.2 to 165 pg/mL). There was, however, hardly any increase of ACTH after CRH stimulation (from 6.05 pg/mL to 10.2 pg/mL), thus 
demonstrating central CRH resistance.
In summary, this patient developed secondary adrenal failure in the setting of previous Addison’s disease. Interestingly, hypoglycaemia 
(but not CRH) provided a stimulus for ACTH release, thus demonstrating CRH resistance. The case confirms that besides CRH, other 
factors are responsible for stimulation of the ACTH-cortisol axis during insulin tolerance test. (Endokrynol Pol 2017; 68 (4): 468–471)
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Streszczenie
Prezentujemy przypadek 36-letniej pacjentki z chorobą Addisona, u której stwierdzono niskie poranne stężenie ACTH.
Wywiad chorobowy: w wieku 23 lat pacjentka była poddana radiojodoterapii z powodu choroby Gravesa i Basedowa. Siedem miesięcy póź-
niej została przyjęta do szpitala z powodu hipotonii z towarzyszącą hiponatremią (sód 109 mmol/l) i niskim porannym stężeniem kortyzolu 
(119 nmol/l). Dalsze badania potwierdziły rozpoznanie pierwotnej niewydolności kory nadnerczy. Oznaczone wówczas stężenie ACTH było 
wysokie i wynosiło 779 pg/ml (N: 0–60 pg/ml). Dziewięć lat później pacjentka została przyjęta do kliniki z powodu znacznego osłabienia. 
W badaniu przedmiotowym nie obserwowano ciemnego zabarwienia skóry, wartości ciśnienia tętniczego były prawidłowe. BMI wynosiło 
22,3 kg/m2. Pacjentka miesiączkowała regularnie. W badaniach laboratoryjnych, pomimo bardzo niskiego stężenia kortyzolu (3,37 nmol/l), 
stwierdzono zaskakująco niskie stężenie ACTH (8,53 pg/ml, N: 0–46 pg/ml). W badaniu RM przysadki nie stwierdzono nieprawidłowości. 
W teście z hipoglikemią poinsulinową uzyskano znaczny wzrost stężenia ACTH (z 15,2 do 165 pg/ml). Natomiast w teście stymulacji z CRH 
wzrost stężenia ACTH był nieznamienny (z 6,05 pg/ml do 10,2 pg/ml). Wyniki te wskazywały na centralną oporność na CRH.
W podsumowaniu, u pacjentki z wcześniej rozpoznaną chorobą Addisona rozwinęła się wtórna niewydolność kory nadnerczy. Brak wzrostu 
stężeń ACTH w teście stymulacji z CRH u tej chorej, przy zachowanej prawidłowej odpowiedzi przysadki w warunkach hipoglikemii, 
potwierdza, że poza CRH również inne czynniki są odpowiedzialne za pobudzenie wydzielania ACTH i kortyzolu w teście hipoglikemii 
poinsulinowej. (Endokrynol Pol 2017; 68 (4): 468–471)
Słowa kluczowe: niewydolność kory nadnerczy, choroba Addisona, przysadka 
Introduction
Addison’s disease may appear as an isolated disorder 
or in concurrency with other autoimmune diseases. 
We present a case report of a patient with primary ad-
renal failure, who subsequently developed an isolated 
corticotrophin deficiency, without evidence of other 
pituitary dysfunction. 
Case report
A 36-year-old Caucasian woman with primary adrenal 
insufficiency diagnosed at the age of 24 years was ad-
mitted to our hospital for metabolic assessment. Prior 
to the diagnosis of Addison’s disease, she had a history 
of Graves’ hyperthyroidism, for which she received 
radioiodine therapy at the age of 23 years, followed by 
thyroxine replacement due to post-ablation hypothy-
Prof. Andrzej Lewinski, M.D., Ph.D., Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital — Research 
Institute, Rzgowska St. 281/289, 93–338 Łódź, Poland, tel.: +48 42 271 11 41, fax: +48 42 271 11 40, e-mail: alewin@csk.umed.lodz.pl
469
Endokrynologia Polska 2017; 68 (4)
O
PI
S 
PR
ZY
PA
D
K
U
for primary adrenal insufficiency (PAI). It is most com-
monly characterised by the presence of 21-hydroxylase 
autoantibodies, which can be found in 70% of cases of 
autoimmune PAI. There have been numerous studies 
confirming high prevalence of other organ-specific 
autoantibodies in patients with Addison’s disease as 
well as frequent development of other autoimmune 
disorders in this population [1, 2]. Some studies also 
demonstrate an association between autoimmune hy-
popituitarism and various autoimmune diseases [3, 4]. 
On that basis the concurrence of primary and second-
ary autoimmune adrenal insufficiency is probable, 
but documented reports of such cases are scarce. In 
contrast to primary adrenal failure, secondary adrenal 
insufficiency is rarely caused by autoimmune processes. 
According to some reports, autoimmune hypophysitis 
accounts for less than 1% of hypopituitarism [5–7]. 
Furthermore, our patient had no clinical features of 
other pituitary disease, with regular periods and normal 
pituitary imaging.
The hormonal diagnostic tests for PAI comprise 
paired measurement of serum cortisol and plasma 
ACTH. Low morning cortisol (< 5 μg/dL or < 140 
nmol/L) strongly suggests adrenal insufficiency, and 
it should be accompanied by elevated ACTH — more 
than two-fold above the upper limit of the reference 
interval [8]. In equivocal cases ACTH stimulation test 
is performed using standard (0.25 mg i.m or i.v.) or 
less often a low dose (0.001 mg — 1 µg) of ACTH syn-
thetic analogue (cosyntropin or tetracosactide) [9, 10]. 
Standard ACTH-stimulated peak serum cortisol should 
exceed 18 µg/dL (500 nmol/L).
We found it intriguing that in our patient low cortisol 
failed to be an adequate stimulus for ACTH secretion 
(it is usually very high in Addison’s disease), but there 
was an increase of ACTH in response to hypoglycaemia 
during ITT. Furthermore, CRH administration also did 
not result in any substantial ACTH release, thus dem-
onstrating CRH resistance. In the case of our patient, 
there were previous results showing high ACTH con-
centrations consistent with Addison’s disease, hence 
development of corticotrophin deficiency and CRH 
resistance must have been a gradual phenomenon. 
As a result of this, our patient demonstrated both 
primary and central adrenal failure due to an isolated 
corticotropin deficiency, with a hypoglycaemia-induced 
increase in ACTH, which appeared independently of 
CRH-related stimulation of ACTH release. Dynamic 
tests for evaluation of the hypothalamic-pituitary-
adrenal axis comprise insulin tolerance test, glucagon 
stimulation test, CRH stimulation test, and metyrapone 
stimulation test [11, 12]. Among all provocative tests, 
insulin-induced hypoglycaemia (ITT) remains the gold 
standard [13–16]. Plasma glucose concentration of less 
roidism. At about the same time she claimed to have 
two episodes of pancreatitis treated with cholecystec-
tomy. About seven months later, she was euthyroid on 
L-thyroxine (TSH 1.51 mIU/mL) but was admitted with 
hypotension and hyponatraemia (sodium 109 mmol/L). 
Further investigations, performed in an academic unit, 
confirmed adrenal failure with low morning cortisol 
(119 nmol/L). On assessment at the age of 26 years 
(2006) her plasma adrenocorticotropic hormone was 
clearly elevated at 779.5 pg/mL (reference range 0–60), 
confirming the diagnosis of primary adrenal insuf-
ficiency. However, during hospitalisation at the age of 
28 years (2008) and at 34 years (2014) her ACTH levels 
were low. The available documentation, however, did 
not include simultaneous cortisol levels; therefore, the 
results were puzzling and difficult to interpret. 
At the age of 36 years she complained about tired-
ness and had an episode of postural syncope. Physical 
examination was unremarkable; specifically, orthostatic 
hypotension was not observed. Her treatment included 
hydrocortisone 20 mg in the morning and 10 mg at 
about 3 p.m., fludrocortisone 75 μg, and L-thyroxine 
75 μg. Her ECG and echocardiogram were normal. Bio-
chemical analysis revealed normal serum electrolytes 
and low concentrations of both plasma morning cortisol 
(0.53 μg/dL [14.7 nmol/L]) and corticotropin (ACTH 
8.6 pg/mL, ref. range 0–46), suggestive of secondary 
rather than primary adrenal insufficiency. Plasma ren-
nin concentration was satisfactory on fludrocortisone 
replacement (31.58 μIU/mL [ref. range: 2.8–39.9 μIU/mL, 
for supine position]), with aldosterone concentration 
of 2.69 ng/dL (ref. range: 1.17–23.6 ng/dL), and DHEAS 
concentration of 15.82 μg/dL (ref. range: 60.9–337 μg/dL). 
Consequently, the patient underwent MRI scanning, 
which did not reveal any abnormality in the pituitary 
region. 
In order to evaluate pituitary function, dynamic 
stimulation tests were performed, including insulin 
tolerance test (ITT) and CRH stimulation test (100 
µg intravenously). Insulin-induced hypoglycaemia 
revealed excellent GH and ACTH secretion, whereas 
cortisol concentrations remained low. Interestingly, 
on performing the CRH stimulation test no significant 
alteration in ACTH level was observed. During hos-
pitalisation the patient’s hydrocortisone replacement 
dose was reduced to 15 mg in the morning and 10 mg 
in the afternoon. The patient was discharged for further 
outpatient follow-up.
Discussion
Our case demonstrates development of an isolated cor-
ticotrophin deficiency in a patient with long-standing 
Addison’s disease. Autoimmunity is the main reason 
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than 2.2 mmol/L is considered an adequate stimulus for 
GH and ACTH release from the pituitary, and cortisol 
levels greater than 500 nmol/L are considered to be 
consistent with normal ACTH status. The stress of the 
hypoglycaemia induces the secretion of ACTH and GH, 
while postulated mechanisms include the release of 
CRH and vasopressin from the hypothalamus [17] , as 
well as adrenergic stimulation [18]. The clinical utility 
of the growth hormone-releasing peptide-2 (GHRP-2), 
as a peptide that stimulates not only GH but also ACTH 
secretion, has recently been proven [19]; however, the 
mechanism in which GHRP-2 induces ACTH secretion 
is poorly defined. 
In our case, we have proven that factors other than 
CRH must have been responsible for stimulation of 
ACTH secretion. The mechanisms responsible for this 
phenomenon remain speculative. Potentially, the effects 
of vasopressin on ACTH release (i.e. independent of 
CRH) might be confirmed by measurements of copep-
tin, a peptide secreted in stoichiometric amounts with 
AVP, which increases concurrently with AVP during 
ITT [20]. Copeptin assays were, however, not available 
in our Department.
The reason (or reasons) for the above-described 
acquired CRH resistance remain speculative, includ-
ing desensitisation of CRH receptor or other adap-
tive factors that might influence saturation of central 
glucocorticoid receptors (GR). For instance, it was 
demonstrated that efflux transporter P-glycoprotein, 
encoded by the ATP-binding cassette B1 (ABCB1) gene 
[21], at the blood-brain barrier, determines penetration 
of several glucocorticoids, thus regulating their intra-
cellular content and access to GR [22]. There are also 
data suggestive that polymorphism of P-glycoprotein 
might determine the amount of intracellular cortisol, 
thus influencing the susceptibility to develop osteo-
porosis in some subjects with Addison’s disease [23]. 
Furthermore, there are experimental data showing that 
in cases of administration of low-dose glucocorticoids 
there might be a dissociation between peripheral and 
central saturation of glucocorticoid receptors [24]. It is 
well-recognised that administration of hydrocortisone 
in doses still used in Poland (20 mg in the morning, 
10 mg in the afternoon), including our patient until her 
last hospital admission, result in supraphysiological 
cortisol peaks. Hence, there is a possibility that, if this 
patient either had a variant of P-glycoprotein associated 
with its reduced function (e.g. rs1045642 [25]) or gradu-
ally developed an acquired P-glycoprotein deficiency, 
then theoretically an excessive penetration of cortisol 
into the central nervous system might have led to cen-
tral suppression of CRH-ACTH secretion. It must be 
pointed out, however, that such a mechanism remains 
purely speculative, while the reason for the above 
described acquired CRH resistance remains unknown. 
Conclusions
The hormonal status of the presented patient suggests 
development of an isolated corticotropin deficiency 
in an individual with a history of Addison’s disease 
(hypercortisolaemia concomitant with low ACTH level, 
with documented markedly elevated ACTH in the 
past). These results show dysfunction of hypothalamic-
pituitary-adrenal feedback loop (absence of ACTH 
response to hypercortisolaemia or CRH stimulation). 
Nevertheless, the pituitary insufficiency in this case is 
relative because a different mechanism of stimulation 
(hypoglycaemia during ITT) proved to be efficient in cor-
ticotroph stimulation and resulted in significant ACTH 
output, as well as intact GH secretion. This case clearly 
demonstrates that several different mechanisms must 
Table I. Results of Insulin Tolerance Test in a 36-year old patient with history of Addison’s disease (Insulin Actrapid® 7 
units — 0.15 units per kilogram)
Tabela I. Wyniki testu z insuliną u 36-letniej pacjentki z chorobą Addisona w wywiadzie (Insulin Actrapid® 7 j. — 0,15 j./kg m.c.
Time 0’ 15’ 30’ 45’ 60’ 90’ 120’ minutes
Glucose 4.16 1.61 1.94 2.72 3.33 3.67 3.68 mmol/L
GH 0.28 – 17.8 20.3 21.1 25.0 20.0 ng/mL
Cortisol 4.44 6.10 6.93 5.82 7.48 4.16 4.44 nmol/L
ACTH 15.3 15.2 165.0 112.0 145.0 54.0 31.8 pg/mL
Table II. Results of CRH test results CRH stimulation test (100 μg i.v) in a 36-year old patient with history of Addison’s disease
Tabela II. Wyniki testu stymulacji z CRH (100 μg i.v.) u 36-letniej pacjentki z chorobą Addisona w wywiadzie
Time –15‘ 0’ 15’ 30’ 60’ 90’ minutes
ACTH 5.95 6.05 8.71 10.20 7.47 8.68 pg/mL
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be responsible for ACTH and GH secretion during ITT. 
From a clinical view-point, it is also known that some 
patients of the Caucasian race with long-standing Ad-
dison’s disease remain hyperpigmented, while others 
have a normal or even pale skin-complexion on stand-
ard therapy. It is a puzzling question, whether blunted 
POMC/ACTH secretion and hence less pronounced mel-
anocyte stimulation might be present in these patients.
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